Início › Câncer de Mama › Missouri

Ensaios clínicos de Câncer de Mama em Missouri

75 estudos para Câncer de Mama estão buscando participantes em locais em Missouri.

Cidades em Missouri

Texto oficial do estudo (Inglês)

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

HCA Midwest Division, Kansas City

RecrutandoFase 3

Idades de 18 a 100 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05827081

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
Central Care Cancer Center - Bolivar, Bolivar
Cox Cancer Center Branson, Branson
e mais 21

RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos

Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05334069

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Washington University, School of Medicine, St Louis

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06172478

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

St. Lukes Hospital of Kansas City, Kansas City
Washington University School of Medicine, St Louis

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06625775

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

Missouri Cancer Associates, Columbia
Saint Luke's Cancer Institute, Kansas City
Oncology Hematology Associates, Springfield
e mais 1

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06369285

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

Washington University in St Louis, St Louis

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT07222267

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Saint Luke's Cancer Institute ( Site 0059), Kansas City
Washington University Siteman Cancer Center ( Site 0031), St Louis

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06966700

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Saint Luke's Cancer Institute ( Site 0027), Kansas City
Washington University School of Medicine ( Site 0076), St Louis

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06312176

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Research Site, St Louis

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06103864

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

Washington University School of Medicine- Siteman Cancer Center, St Louis

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07007559

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Local Institution - 0140, St Louis

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT06618287

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Clinical Trial Site, Kansas City

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT07085767

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Mercy Health - Sindelar Cancer Center, St Louis
Mercy Health - Pratt Cancer Center, St Louis

Recrutando

Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT07214532

Cognitive Rehabilitation Following Breast Cancer Treatment

University of Missouri, Columbia

Recrutando

Idades de 20 a 75 · Mulheres · Atualizado em 22 de set. de 2026 · NCT06545045

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Saint Luke's Cancer Institute, Kansas City
Oncology Hematology Associates, Springfield

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07174336

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

Washington University, St Louis

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07114601

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

Washington University School of Medicine, St Louis

RecrutandoFase 2

Idades 18 e acima · Mulheres · Atualizado em 22 de set. de 2026 · NCT07287098

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Washington University School of Medicine in St. Louis, St Louis

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07213791

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

Saint Luke's Hospital of Kansas City, Kansas City

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT07173751

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Washington Univ. School of Medicine, St Louis

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT07109726

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

Saint Luke's Hospital of Kansas City, Kansas City
Washington University School of Medicine, St Louis

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT06827236

Precision Supplemental Imaging in Women With Dense Breasts

Washington University School of Medicine, St Louis

RecrutandoVoluntários saudáveis bem-vindos

Idades de 25 a 55 · Mulheres · Atualizado em 16 de set. de 2026 · NCT07277738

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Siteman Cancer Center, St Louis

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 15 de set. de 2026 · NCT06492616

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

Research Site, St Louis

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 11 de set. de 2026 · NCT05123482

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Saint Luke's Cancer Institute, Kansas City
Washington University School of Medicine, St Louis

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 9 de set. de 2026 · NCT06253871

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

Washington University School of Medicine, St Louis

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 9 de set. de 2026 · NCT06440005

A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

Washington University Medical School, St Louis

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT05307705

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Washington University Siteman Cancer Center, St Louis

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT07100106

To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

HCA Midwest Division, Kansas City

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 4 de set. de 2026 · NCT07368998

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Washington University School of Medicine- Siteman Cancer Center, St Louis

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 3 de set. de 2026 · NCT06982521

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

Oncology Hematology Associates, Springfield

RecrutandoEstudo observacional

Idades de 18 a 99 · Todos os sexos · Atualizado em 3 de set. de 2026 · NCT07211178

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

HCA Midwest Health, Kansas City

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 3 de set. de 2026 · NCT06790693

Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women

Washington University School of Medicine, St Louis

RecrutandoEstudo observacional

Idades de 18 a 50 · Mulheres · Atualizado em 2 de set. de 2026 · NCT06904365

The Vanguard Study: Testing a New Way to Screen for Cancer

Saint Luke's Hospital of Kansas City, Kansas City
Washington University School of Medicine, St Louis

RecrutandoVoluntários saudáveis bem-vindos

Idades de 45 a 75 · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT06995898

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
Central Care Cancer Center - Bolivar, Bolivar
Cox Cancer Center Branson, Branson
e mais 29

RecrutandoFase 3

Idades de 18 a 60 · Mulheres · Atualizado em 2 de set. de 2026 · NCT05879926

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Washington University, St Louis

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 28 de ago. de 2026 · NCT07029399

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

WA Uni School Of Med, St Louis

RecrutandoFase 1/2

Idades de 18 a 100 · Todos os sexos · Atualizado em 27 de ago. de 2026 · NCT06726148

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

Washington University School of Medicine - Siteman Cancer Center, St Louis

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 26 de ago. de 2026 · NCT07383506

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

Washington University, Siteman Cancer Center, St Louis

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 21 de ago. de 2026 · NCT06774963

Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry

Universtiy Health, Kansas City
KCCC South, Kansas City
Research Medical Center, Kansas City
e mais 2

RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos

Todas as idades · Todos os sexos · Atualizado em 18 de ago. de 2026 · NCT02302742

Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.